James Rowley
Nurse Practitioner · Sierra Vista, AZNPI 1053806042
Payments from drug & device makers
Across 244 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$862
- AbbVie$708
- AstraZeneca$632
- Novo Nordisk$317
- Lilly USA, LLC$265
- GSK$238
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,783100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 32 | $862 |
| AbbVie | 36 | $708 |
| AstraZeneca | 26 | $632 |
| Novo Nordisk | 23 | $317 |
| Lilly USA, LLC | 19 | $265 |
| GSK | 13 | $238 |
| Novartis | 11 | $215 |
| Pfizer | 12 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $152 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $105 |
| Abbott | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Dexcom, Inc. | 2 | $70 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Penumbra, Inc. | 1 | $57 |
| Boehringer Ingelheim | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Exact Sciences | 3 | $48 |
| Bioventus LLC | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Johnson & Johnson | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Biogen | 1 | $18 |
| Merck | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,795 in reported general payments places this provider in the 90th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $84,672 |
| FarxigaDapagliflozin Propanediol | 83 | $80,891 |
| EliquisApixaban | 85 | $73,229 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $58,393 |
| TrulicityDulaglutide | 48 | $55,946 |
| XifaxanRifaximin | 16 | $49,117 |
| JardianceEmpagliflozin | 40 | $42,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $31,192 |
| ProliaDenosumab | 17 | $28,848 |
| XareltoRivaroxaban | 19 | $25,568 |
| KeppraLevetiracetam | 13 | $19,901 |
| MyrbetriqMirabegron | 15 | $14,724 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $14,361 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,065 |
| BelbucaBuprenorphine Hcl | 11 | $8,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $632 | $121,149124 claims |
| Novo NordiskOzempic | $317 | $84,67253 claims |
| PfizerEliquis | $188 | $73,22985 claims |
| GSKTrelegy Ellipta | $238 | $58,39351 claims |
| Lilly USA, LLCTrulicity | $265 | $55,94648 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $152 | $49,11716 claims |
| Boehringer IngelheimJardiance | $51 | $42,68440 claims |
| AmgenProlia | $862 | $28,84817 claims |
| Johnson & JohnsonXarelto | $36 | $25,56819 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $14,72415 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $63 | $8,10111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Sierra Vista
- Ann MooreGlendale$2.1M
- Andrea KesslerLitchfield Park$780K
- Sandra KurtinTucson$201K
- Kristen HerzogScottsdale$162K
- Krista ArredondoChandler$133K
- Shannon MorgensternOro Valley$71K
- Helena In't VeldPhoenix$64K
- Steven KalfusChandler$43K
- Dustin NickersonPhoenix$39K
- Shannon BoffeliFlagstaff$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.